Medipal Posts Higher Sales and Profits, Lifts Dividend but Guides to Softer Earnings

Medipal Holdings ( (JP:7459) ) has provided an announcement.

Medipal Holdings reported a 4.0% rise in consolidated net sales to ¥3.82 trillion for the year ended March 31, 2026, while operating profit slipped 4.4% to ¥53.2 billion but ordinary profit climbed 16.0% to ¥75.7 billion on stronger equity-method earnings. Profit attributable to owners of the parent increased 5.6% to ¥42.5 billion, net assets and total assets both expanded, and cash and cash equivalents rose, indicating a generally solid financial position despite pressure on operating margins.

The company lifted its annual dividend to ¥66 per share for fiscal 2026 and plans a further increase to ¥68 for fiscal 2027, keeping payout and net-asset ratios broadly stable to reward shareholders. For the year to March 2027, Medipal forecasts modest sales and operating profit growth but expects declines in ordinary profit and bottom-line earnings, while recent portfolio adjustments and the consolidation of Cygni Holdings and Cygni Corporation signal ongoing reshaping of its business structure and asset mix.

The most recent analyst rating on (JP:7459) stock is a Hold with a Yen2700.00 price target. To see the full list of analyst forecasts on Medipal Holdings stock, see the JP:7459 Stock Forecast page.

More about Medipal Holdings

Medipal Holdings is a Tokyo-listed company operating in Japan’s healthcare distribution sector, handling pharmaceuticals, medical supplies and related products. Through a nationwide logistics and wholesale network, it supplies drugs and healthcare items to hospitals, pharmacies and other medical institutions, positioning itself as a key intermediary in the Japanese medical supply chain.

Average Trading Volume: 417,105

Technical Sentiment Signal: Buy

Current Market Cap: Yen505.9B

For an in-depth examination of 7459 stock, go to TipRanks’ Overview page.